Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Epizyme Inc (EPZM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 733,225
  • Shares Outstanding, K 69,500
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -134,310 K
  • 36-Month Beta 2.01
  • Price/Sales 74.72
  • Price/Cash Flow N/A
  • Price/Book 3.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.59
  • Number of Estimates 8
  • High Estimate -0.43
  • Low Estimate -0.83
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +6.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.61 +22.53%
on 08/02/18
14.25 -25.96%
on 07/26/18
-3.05 (-22.43%)
since 07/17/18
3-Month
8.61 +22.53%
on 08/02/18
18.70 -43.58%
on 05/24/18
-6.40 (-37.76%)
since 05/17/18
52-Week
8.61 +22.53%
on 08/02/18
21.40 -50.70%
on 03/13/18
-3.55 (-25.18%)
since 08/17/17

Most Recent Stories

More News
Shares of EPZM Down 30.3% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Epizyme Inc (NASDAQ:EPZM) on June 15th, 2018 at $15.43. In approximately 2 months, Epizyme Inc has returned 30.31% as of today's recent price of $10.75.

EPZM : 10.55 (-1.86%)
Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks

Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months....

RARE : 78.10 (+0.23%)
GILD : 72.92 (-3.53%)
VNDA : 21.85 (-0.91%)
EPZM : 10.55 (-1.86%)
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

Epizyme (EPZM) delivered earnings and revenue surprises of 20.75% and 458.14%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

EPZM : 10.55 (-1.86%)
Epizyme (EPZM) Reports Narrower-than-Expected Q2 Loss

Epizyme (EPZM) reports narrower-than-expected loss and revenues beat estimates in the second quarter of 2018.

EPZM : 10.55 (-1.86%)
What's in Store for Epizyme (EPZM) This Earnings Season?

Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.

ENDP : 15.64 (-1.94%)
RHHBY : 30.1200 (+0.57%)
PCRX : 46.35 (+0.32%)
EPZM : 10.55 (-1.86%)
Epizyme Inc Has Returned 19.6% Since SmarTrend Recommendation (EPZM)

SmarTrend identified a Downtrend for Epizyme Inc (NASDAQ:EPZM) on June 15th, 2018 at $15.43. In approximately 2 month, Epizyme Inc has returned 19.61% as of today's recent price of $12.40.

EPZM : 10.55 (-1.86%)
Shares of Mirati Therapeut Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (MRTX, EPZM , XON , PTCT , TTOO)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

XON : 14.36 (+1.13%)
TTOO : 6.45 (-0.62%)
MRTX : 59.95 (+1.87%)
EPZM : 10.55 (-1.86%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Epizyme Inc (EPZM , OPK , VTL, CARA , SRNE)

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

SRNE : 5.35 (+0.94%)
OPK : 5.61 (+2.19%)
EPZM : 10.55 (-1.86%)
VTL : 9.00 (-1.10%)
Stock Performance Review on Exelixis and Three Other Biotech Stocks

Stock Research Monitor: ECYT, EPZM, and ESPR

ESPR : 48.12 (+3.11%)
ECYT : 17.94 (+5.16%)
EXEL : 19.20 (-1.94%)
EPZM : 10.55 (-1.86%)
Epizyme Reports Positive Updated Interim Data from Phase 2 Study of Tazemetostat in Patients With Relapsed or Refractory Follicular Lymphoma at the Congress of the European Hematology Association (EHA)

-- Consistently High Responses in Patients with an EZH2 Activating Mutation

EPZM : 10.55 (-1.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade EPZM with:

Business Summary

Epizyme, Inc. is a biopharmaceutical company. It engages in the discovery, development, planning, and commercialization of therapeutics for cancers. Epizyme, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 10.95
1st Resistance Point 10.75
Last Price 10.55
1st Support Level 10.40
2nd Support Level 10.25

See More

52-Week High 21.40
Fibonacci 61.8% 16.51
Fibonacci 50% 15.00
Fibonacci 38.2% 13.50
Last Price 10.55
52-Week Low 8.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar